Development of new injectable bulking agents: Biocompatibility of radiopaque polymeric microspheres studies in a mouse model

被引:22
作者
Emans, PJ
Saralidze, K
Knetsch, MLW
Gijbels, MJJ
Kuijer, R
Koole, LH
机构
[1] Univ Maastricht, Fac Med, Ctr Biomat Res, NL-6200 MD Maastricht, Netherlands
[2] Eindhoven Univ Technol, Fac Biomed Engn, NL-5600 MB Eindhoven, Netherlands
[3] Cardiovasc Res Inst Maastricht, Dept Mol Genet, Maastricht, Netherlands
[4] Cardiovasc Res Inst Maastricht, Dept Pathol, Maastricht, Netherlands
关键词
radiopacity; microsphere; bulking agent; stress urinary incontinence; biocompatibility;
D O I
10.1002/jbm.a.30293
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Radiopaque polymeric microspheres have a potential as new bulking agents for treatment of stress urinary incontinence (SUI). The advantage over existing bulking agents ties in their X-ray visibility in situ; other polymeric bulking agents (e.g., PTFE or silicone rubbers) are practically radiolucent (i.e., incapable of absorbing X-radiation). Radiopacity is useful in practice because of the high spatial accuracy of X-ray imaging. For instance, X-ray fluoroscopy can be used to assess possible migration of the bulking agent over time or to provide guidance in cases in which a second injection of a bulking agent is necessary (repeated treatment of SUI). Biocompatibility of injected radiopaque microspheres was investigated in vivo by using the mouse as a model. Microspheres were injected subcutaneously (9 animals) or intramuscularly (9 animals), and follow-up was 8 days or 3 months. X-ray fluoroscopy gave clear images of the miscrospheres as an ensemble, and it was found that no migration occurred during 3 months. Histopathology confirmed that all microspheres stayed close to the site of the injection. The microspheres appeared to be well tolerated; only a few giant cells, manifesting a mild inflammatory reaction, were encountered. At 3 months, cappillary blood vessels were observed throughout the microsphere beds, and macrophages and fibroblast cells were seen in between the microspheres. This is encouraging with respect to the intended application, although it must be acknowledged that the data refer merely to a mouse model. Further experiments with larger, more representative models (rabbit and goat) are in progress. (c) 2005 Wiley Periodicals, Inc.
引用
收藏
页码:430 / 436
页数:7
相关论文
共 25 条
[1]   Stability of radiopaque iodine-containing biomaterials [J].
Aldenhoff, YBJ ;
Kruft, MAB ;
Pijpers, AP ;
van der Veen, FH ;
Bulstra, SK ;
Kuijer, R ;
Koole, LH .
BIOMATERIALS, 2002, 23 (03) :881-886
[2]  
BERG S, 1973, ARCH SURG-CHICAGO, V107, P379
[3]   Delivery of LMW heparin via surface coated chitosan/peg-alginate microspheres prevents thrombosis [J].
Chandy, T ;
Rao, GHR ;
Wilson, RF ;
Das, GS .
DRUG DELIVERY, 2002, 9 (02) :87-96
[4]  
CLAES H, 1989, J UROLOGY, V142, P821
[5]   A new delivery system for antisense therapy: PLGA microspheres encapsulating oligonucleotide/polyethyleneimine solid complexes [J].
De Rosa, G ;
Bochot, A ;
Quaglia, F ;
Besnard, M ;
Fattal, E .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2003, 254 (01) :89-93
[6]  
Dmochowski R R, 2001, Tech Urol, V7, P110
[7]   The use of periurethral injectables in the treatment of genuine stress incontinence [J].
Duckett, JRA .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1998, 105 (04) :390-396
[8]   PERIURETHRAL GRANULOMA - UNUSUAL COMPLICATION OF TEFLON PERIURETHRAL INJECTION [J].
FERRO, MA ;
SMITH, JHF ;
SMITH, PJB .
UROLOGY, 1988, 31 (05) :422-423
[9]   PARTICULATE SILICONE FOR USE IN PERIURETHRAL INJECTIONS - LOCAL TISSUE EFFECTS AND SEARCH FOR MIGRATION [J].
HENLY, DR ;
BARRETT, DM ;
WEILAND, TL ;
OCONNOR, MK ;
MALIZIA, AA ;
WEIN, AJ .
JOURNAL OF UROLOGY, 1995, 153 (06) :2039-2043
[10]   Biodegradable PLGA microspheres loaded with ganciclovir for intraocular administration.: Encapsulation technique, in vitro release profiles, and sterilization process [J].
Herrero-Vanrell, R ;
Ramirez, L ;
Fernandez-Carballido, A ;
Refojo, MF .
PHARMACEUTICAL RESEARCH, 2000, 17 (10) :1323-1328